- Home
- PTGX vs RDNT Comparison
PTGX vs RDNT Comparison
Compare PTGX & RDNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | RDNT |
|---|---|---|
| Founded | 2006 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.4B |
| IPO Year | 2016 | 1986 |
Fundamental Metrics
Financial Performance| Metric | PTGX | RDNT |
|---|---|---|
| Price | $89.29 | $78.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $86.44 | $83.60 |
| AVG Volume (30 Days) | 886.1K | ★ 892.0K |
| Earning Date | 11-06-2025 | 11-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | $209,217,000.00 | ★ $1,969,599,000.00 |
| Revenue This Year | N/A | $11.77 |
| Revenue Next Year | $296.47 | $10.76 |
| P/E Ratio | $124.09 | ★ N/A |
| Revenue Growth | N/A | ★ 11.09 |
| 52 Week Low | $33.70 | $45.00 |
| 52 Week High | $93.25 | $85.84 |
Technical Indicators
Market Signals| Indicator | PTGX | RDNT |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 47.28 |
| Support Level | $83.52 | $77.62 |
| Resistance Level | $90.85 | $81.35 |
| Average True Range (ATR) | 2.63 | 3.05 |
| MACD | -0.33 | -0.28 |
| Stochastic Oscillator | 83.62 | 30.64 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About RDNT RadNet Inc.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.